Endocrine Abstracts

Patients receiving parenteral forms of treatment for osteoporosis (e.g. denosumab (DMAB) and zoledronic acid (ZOL)) should be vitamin D replete prior to administration, to minimise the risk of hypocalcaemia. Most patients receiving DMAB or ZOL take supplemental (calcium and) vitamin D but it is widely accepted that adherence to calcium and vitamin D is poor. Frequency of testing 25-hydoxyvitamin D (25OHD), calcium and renal function varies widely between centres in the UK. In ...